Clinical Trials Logo

Clinical Trial Summary

Pegylated liposomal doxorubicin (PLD) was an anthracycline nanomedicine to be approved for advanced breast cancer and other solid tumor therapy and showed a good disease control rate (57%). PLD could induce hypersensitivity reaction (HSR). There are about 9-25% patients got infusion reaction or HSR. Severe HSR could lead to allergic shock even presyncope or threat to life. To our knowledge, there were no sensitivity biomarker to predict the PLD induced HSR. And the mechanism of PLD induced HSR is unknown yet. Therefore, to analyze and discuss the biomarkers and mechanism of PLD induced HSR in advanced breast cancer, we design this prospective, observational, biomarker study.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05181202
Study type Observational [Patient Registry]
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Wei Zhuang, Dr.
Phone +86-13427526343
Email [email protected]
Status Recruiting
Start date February 7, 2021
Completion date June 30, 2023